tirzepatide surpass trials SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Effect of tirzepatide versus insulin
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19





















